Web Cast Announcing Promising News from ASCO for Early Breast Cancer Patients

Orlando, Florida (ots/PRNewswire) - - Landmark Study Big 1-98 Shows Letrozole Offers Greater Protection from Recurrence of Early Breast Cancer than Tamoxifen - Web Cast Briefing Available at 17 May 2005 8:00 AM EDT http://www.ibcsg.org/index.shtm Newly updated results of the independent Breast International Group 1-98 trial just released at ASCO show initial treatment with letrozole, also known as Femara(R), offers significantly greater post-surgery protection against breast cancer recurrence than does tamoxifen, in postmenopausal women with early breast cancer. Findings Confirm: - Letrozole out-performed tamoxifen with a 19% (p=0.003) reduction in risk of breast cancer recurrence - Letrozole demonstrated greater disease free survival in two patient subgroups that are at highest risk: - Node-positive: 29% risk reduction - Prior chemotherapy: 30% risk reduction - Letrozole reduced the risk of cancer spreading to other parts of the body (distant metastases) by 27% (p=0.0012) This Web cast presents updated BIG 1-98 trial results presented at the 2005 annual meeting of the American Society for Clinical Oncology (ASCO) and an understanding of what the trial results mean for patients. WHERE: Click on the following link and view the Web cast data presentation: http://www.ibcsg.org/index.shtm WHO: Dr. John Forbes, University of Newcastle, Newcastle Mater Hospital, Australia and BIG 1-98 Investigator CONTACTS: For questions or to arrange an interview with Dr. John Forbes, please contact: Rum Ekhtiar Nadia Munarini, PhD Ruder Finn IBCSG Phone: +1-212-593-5821 Phone: +41-31-389-92-27 Mobile: +1-917-331-1690 Mobile: +41-79-207-45-82 Web site: http://www.ibcsg.org/index.shtm ots Originaltext: IBCSG Im Internet recherchierbar: http://www.presseportal.ch Contact: Rum Ekhtiar of Ruder Finn, +1-212-593-5821, Mobile: +1-917-331-1690, for IBCSG; or Nadia Munarini, PhD of IBCSG, +41-31-389-92-27, Mobile: +41-79-207-45-82

Das könnte Sie auch interessieren: